Autosomal recessive spinocerebellar ataxia 14 (SCAR14) is a rare, inherited brain disorder. It mainly affects the cerebellum, which controls balance, movement, and eye control. Children usually show delayed milestones first. They may sit, stand, or walk later than other children. As they grow, unsteady walking and poor coordination appear. Eye movement problems are common. Brain scans often show shrinkage (atrophy) of the cerebellum. Thinking and learning problems can occur. SCAR14 is caused by harmful changes (variants) in a gene called SPTBN2, and a child must inherit one non-working copy from each parent. malacards.org+2alliancegenome.org+2
Autosomal recessive spinocerebellar ataxia 14 (SCAR14) is a rare, inherited brain disorder that mainly affects the cerebellum, the part of the brain that controls balance, eye movements, speech, and coordination. Children usually have global developmental delay and later develop gait ataxia (unsteady walking), hand clumsiness, abnormal eye movements, and sometimes intellectual disability. Brain scans often show cerebellar atrophy (shrinkage). “Autosomal recessive” means a child must inherit a faulty gene from both parents to be affected. SCAR14 is most often caused by pathogenic variants in SPTBN2, the gene that codes for β-III spectrin, a structural protein that keeps nerve cell membranes and synapses stable in the cerebellum. malacards.org+2PLOS+2
How it differs from “SCA14.” Medical names can be confusing: SCA14 (without “autosomal recessive”) usually refers to a dominant ataxia linked to the PRKCG gene, which is a different disease and inheritance pattern. In contrast, SCAR14 is recessive and most often involves SPTBN2. Using the correct name prevents mix-ups in genetic testing and counseling. Wikipedia
Scientifically, SPTBN2 encodes β-III spectrin, a scaffold protein that helps Purkinje cells in the cerebellum keep their shape and move cargo inside the cell. When β-III spectrin does not work, Purkinje cells malfunction and slowly degenerate. This leads to ataxia and eye movement problems. Homozygous or compound-heterozygous SPTBN2 variants are the usual cause of SCAR14. genecards.org+1
Other names
This condition is also called:
- SCAR14 (Spinocerebellar ataxia, autosomal recessive 14)
- Spectrin-associated autosomal recessive cerebellar ataxia
- SPTBN2-related autosomal recessive cerebellar ataxia
- Autosomal recessive spinocerebellar ataxia type 14
All of these names refer to the same disorder linked to recessive SPTBN2 variants. orpha.net+1
Types
There are no official subtypes inside SCAR14, but doctors often group patients by age at onset and key features. These “types” are practical categories to help with care and counseling:
Infantile-onset SCAR14 – global developmental delay in infancy, early hypotonia, very early gait ataxia, and eye movement problems; cerebellar atrophy is common on MRI. malacards.org
Childhood-onset SCAR14 – delayed motor milestones, unsteady gait in early childhood, limb incoordination, speech delay or dysarthria, and cerebellar atrophy on MRI. malacards.org
SCAR14 with prominent eye movement signs – noticeable nystagmus, hypometric saccades, jerky pursuit, and convergent squint alongside gait ataxia. malacards.org
SCAR14 with intellectual disability – various levels of learning difficulty combined with ataxia and cerebellar atrophy. malacards.org
(These categories reflect patterns reported across summaries of recessive SPTBN2 disease; they are not official genetic subtypes.) malacards.org
Causes
Remember: SCAR14 is monogenic—the root cause is harmful variants in SPTBN2. Below are 20 practical “causes” describing the specific ways variants and downstream biology lead to disease expression:
Biallelic SPTBN2 loss-of-function variants (both copies altered) cause Purkinje cell dysfunction and ataxia. zfin.org
Nonsense (stop) variants truncate β-III spectrin, producing unstable or non-functional protein. genecards.org
Frameshift variants change the reading frame and disrupt key spectrin domains. genecards.org
Splice-site variants mis-splice the RNA, removing or altering essential segments. genecards.org
Missense variants in critical repeats alter spectrin folding and stability. genecards.org
Compound heterozygosity (two different harmful variants, one on each copy) results in β-III spectrin failure. zfin.org
Defective spectrin–actin network weakens the neuronal scaffold in Purkinje cells. genecards.org
Impaired dendritic architecture disrupts Purkinje cell dendrite growth and branching. (Shown broadly for spectrin/PKCγ-Purkinje biology.) PMC
Abnormal membrane protein trafficking reduces delivery of ion channels and receptors to synapses. genecards.org
Disrupted glutamate receptor handling affects Purkinje cell input and cerebellar signaling. genecards.org
Disturbed calcium homeostasis in Purkinje cells adds to firing instability. genecards.org
Axonal transport problems impede movement of cargo along Purkinje axons. genecards.org
Synaptic dysfunction weakens communication within cerebellar circuits. genecards.org
Progressive Purkinje cell degeneration leads to cerebellar atrophy on MRI. malacards.org
Developmental vulnerability of the cerebellum explains infantile or childhood onset. malacards.org
Homozygous hot-spot variants in SPTBN2 reported in families with severe early disease. malacards.org
Gene–environment neutrality (no proven environmental trigger), emphasizing genetic causation. malacards.org
No dominant-negative effect in SCAR14 (recessive), unlike PRKCG-related dominant SCA14—different gene and mechanism. NCBI+1
Distinct from SPTBN2-dominant SCA5—same gene can cause another ataxia when variants are heterozygous/dominant. genecards.org
Genetic founder effects in some populations may cluster specific SPTBN2 variants. (Inferred from case-series patterns in rare disease databases.) malacards.org
Symptoms
Unsteady gait – walking is wide-based and wobbly; the child may fall often. malacards.org
Poor limb coordination – hands overshoot or undershoot targets (dysmetria). malacards.org
Slow rapid-alternating movements – trouble with fast hand or foot taps (dysdiadochokinesia). malacards.org
Eye movement problems – nystagmus, jerky pursuit, or small saccades. malacards.org
Speech problems – slurred or scanning speech (dysarthria). malacards.org
Developmental delay – late sitting, standing, or walking. malacards.org
Hypotonia – low muscle tone in infancy. malacards.org
Truncal ataxia – trouble sitting or standing still without swaying. malacards.org
Tremor – shaking of hands during action. malacards.org
Learning difficulties – mild to severe intellectual disability may be present. malacards.org
Fatigue with walking – extra effort due to poor balance. malacards.org
Frequent falls – common in childhood during play. malacards.org
Difficulty with fine motor tasks – buttons, small toys, or handwriting are hard. malacards.org
Feeding or swallowing issues – sometimes present because of coordination problems. malacards.org
Emotional frustration – children may feel upset by slow progress and repeated falls; this is common in chronic ataxias. malacards.org
Diagnostic tests
A) Physical examination (at the bedside)
Gait observation – the doctor watches how the child walks and turns; a wide-based, sway-prone gait suggests cerebellar ataxia. malacards.org
Romberg test – standing with feet together and eyes closed; increased sway suggests balance system problems. (Standard ataxia assessment.) malacards.org
Finger-to-nose – the child tries to touch their nose smoothly; overshoot shows dysmetria. malacards.org
Heel-to-shin – sliding the heel down the opposite shin tests leg coordination; wobble indicates ataxia. malacards.org
Rapid alternating movements – quick hand flips test cerebellar timing; slowness or irregular rhythm supports ataxia. malacards.org
B) Manual/bedside oculomotor tests
Saccade testing – the doctor asks the child to look quickly between two targets; small or slow jumps suggest cerebellar control issues. malacards.org
Smooth pursuit – following a moving finger; jerky pursuit is typical in cerebellar disease. malacards.org
Nystagmus check – brief eye beats at rest or gaze; common in cerebellar syndromes like SCAR14. malacards.org
C) Laboratory and pathological tests
Targeted gene panel for ataxia – looks for SPTBN2 variants along with many other ataxia genes; useful first genetic test in many clinics. invitae.com
Whole-exome sequencing (WES) – examines coding genes; helps when panel is negative or when family history is unclear. invitae.com
Parental testing – confirms autosomal recessive inheritance by showing one variant in each parent. zfin.org
Basic metabolic screen – glucose, electrolytes, thyroid, vitamin E/B12, lactate, ammonia; this helps rule out other treatable ataxias. (Standard practice in ataxia workups.) malacards.org
Creatine kinase (CK) – usually normal, but can exclude myopathy as a main cause of motor delay. (General neuromuscular screening.) malacards.org
D) Electrodiagnostic tests
EEG – used when spells suggest seizures or staring episodes; seizures are not core to SCAR14, but some recessive ataxias have them. orpha.net
EMG and nerve conduction studies – help rule out peripheral neuropathy if numbness or weakness is suspected; SCAR14 is primarily cerebellar. malacards.org
Evoked potentials (visual or somatosensory) – can show slowed brain pathway signals; sometimes used in complex ataxia evaluations. malacards.org
E) Imaging tests
Brain MRI – key test; often shows cerebellar atrophy (shrinkage), which supports the diagnosis together with symptoms and genetics. malacards.org
Tensor imaging or volumetry (advanced MRI) – research-level tools that quantify cerebellar pathway changes; used in specialized centers. malacards.org
Spine MRI – not routine, but may be done to rule out other causes of gait problems if signs point to the spinal cord. (General ataxia workup logic.) malacards.org
Oculography (video eye tracking) – documents nystagmus and saccade metrics; helpful for objective follow-up. (Used in ataxia clinics and studies.) malacards.org
Non-pharmacological treatments (therapies & other supports)
Physiotherapy (coordination & balance training).
Purpose: improve walking, standing, and limb control; reduce falls.
Mechanism: repeated, task-specific practice strengthens preserved circuits and teaches the brain to compensate for cerebellar errors. Meta-analyses show physiotherapy reduces ataxia severity and improves gait without major harms. PMC+1Gait and posture retraining (treadmill, over-ground practice).
Purpose: steadier steps and safer turns.
Mechanism: repetitive stepping with feedback refines motor patterns and increases confidence; programs often blend balance, strength, and aerobic blocks. Taylor & Francis OnlineCore stability and trunk control exercises (home-based).
Purpose: better midline control to cut sway and improve transfers.
Mechanism: targeted core activation improves anticipatory postural adjustments; short home programs show benefits in trunk function and gait speed. movementdisorders.onlinelibrary.wiley.comSpeech-language therapy.
Purpose: clearer speech and safer swallowing.
Mechanism: pacing, breath control, and articulation drills help dysarthria; swallowing therapy lowers aspiration risk with compensatory strategies. pn.bmj.comOccupational therapy & adaptive equipment.
Purpose: independence in daily tasks (feeding, dressing, writing).
Mechanism: task simplification, weighted utensils, grab bars, and home modifications reduce energy cost and fall risk. pn.bmj.comFalls prevention (home safety, footwear, canes/walkers).
Purpose: fewer injuries.
Mechanism: hazard removal, proper shoes, and appropriate mobility aids lower the center of mass sway and prevent missteps. pn.bmj.comVision & oculomotor rehabilitation.
Purpose: reduce oscillopsia and reading difficulty.
Mechanism: gaze-stabilization and saccade control exercises teach compensatory eye-head strategies. PMCNutrition support for underweight or fatigue.
Purpose: maintain weight and strength.
Mechanism: high-calorie, protein-adequate diets and texture modification for dysphagia; early dietitian input prevents malnutrition. BioMed CentralSwallowing safety & early feeding-tube planning (if needed).
Purpose: prevent aspiration and weight loss when swallowing is unsafe.
Mechanism: if long-term tube feeding is necessary, guidelines support PEG after prolonged dysphagia; decisions are individualized. gutnliver.org+1Powered mobility (scooter/wheelchair) when fatigue or falls limit walking.
Purpose: maintain community access and reduce injuries.
Mechanism: conserves energy for therapy and personal goals. pn.bmj.comOrthotics & splints (e.g., ankle-foot orthoses).
Purpose: improve foot clearance and stance stability.
Mechanism: braces reduce ankle instability and ataxic foot placement. pn.bmj.comBone health program.
Purpose: lower fracture risk from falls.
Mechanism: vitamin D/calcium optimization and weight-bearing where safe. pn.bmj.comFatigue management & energy conservation.
Purpose: extend functional time each day.
Mechanism: pacing, activity scheduling, and rest blocks reduce overuse. pn.bmj.comCognitive and educational supports.
Purpose: maximize learning/communication if intellectual disability present.
Mechanism: individualized education plans and assistive tech. malacards.orgMental-health care (CBT, supportive counseling).
Purpose: treat anxiety/depression common in chronic neurologic disease.
Mechanism: coping skills improve participation in rehab. pn.bmj.comSleep hygiene & treatment of sleep problems.
Purpose: better daytime function and balance.
Mechanism: structured sleep routines and addressing apnea/insomnia. pn.bmj.comCommunity exercise (cycling, aquatic therapy).
Purpose: endurance and symmetric practice with low fall risk.
Mechanism: rhythmic, supported movement refines timing. Taylor & Francis OnlineCaregiver training & respite.
Purpose: safer transfers and reduced caregiver strain.
Mechanism: proper techniques and scheduled breaks. pn.bmj.comAdvanced mobility tech (smart canes, inertial sensors).
Purpose: feedback for step length and sway.
Mechanism: objective measures track progress and adjust therapy. NatureMultidisciplinary clinic follow-up.
Purpose: coordinated care (neurology, rehab, genetics, nutrition, mental health).
Mechanism: integrated plans improve safety and quality of life. pn.bmj.com
Drug treatments
No drug is FDA-approved specifically for SCAR14. Below are commonly used, evidence-informed options for symptoms seen in cerebellar ataxias; always individualize with a neurologist. FDA labels are cited to show dosing/safety information; indications there may differ.
Baclofen (oral). For spasticity and stiffness. Start low and titrate. Watch for drowsiness and weakness. FDA label provides dosing and cautions (esp. CNS effects). FDA Access Data
Tizanidine. Alternative antispastic agent; can cause sedation and low blood pressure; monitor LFTs. FDA label supports dose guidance. FDA Access Data
Clonazepam. Helpful for myoclonus, tremor, and sleep; risk of sedation and dependence; taper slowly. FDA label details warnings. FDA Access Data
Levetiracetam. For seizures/myoclonus; generally well-tolerated; monitor mood effects. FDA label provides dosing ranges. FDA Access Data
Valproate. Broad-spectrum antiseizure; may reduce myoclonus but has hepatotoxicity and teratogenicity risks; monitor platelets/LFTs. FDA label. FDA Access Data
Topiramate. Can help tremor or seizures; watch for cognitive slowing and paresthesias; hydrate to prevent stones. FDA label. FDA Access Data
Gabapentin. For limb tremor/neuropathic pain; sedation and dizziness possible. FDA label provides dosing information. FDA Access Data
Pregabalin. Similar to gabapentin for neuropathic symptoms and anxiety; adjust dose in renal impairment. FDA label. FDA Access Data
Propranolol (long-acting). Evidence-based for essential tremor; sometimes tried for cerebellar tremor; monitor bradycardia and bronchospasm. FDA label; review summarizing ET approval. FDA Access Data+1
Primidone. Alternative for tremor where tolerated; start very low to avoid sedation/ataxia worsening. FDA label (Mysoline). FDA Access Data
OnabotulinumtoxinA (Botox®). For focal dystonia, tremor in specific muscles, blepharospasm, and sialorrhea; administered by trained clinicians. FDA labels list approved indications and safety. FDA Access Data+1
Memantine. Sometimes helps acquired pendular nystagmus or oscillopsia; main approval is Alzheimer’s disease; monitor for dizziness/confusion. FDA labels. FDA Access Data+1
Acetazolamide. May improve episodic ataxia or downbeat nystagmus in select cases; monitor electrolytes and for paresthesias. FDA labels (Diamox). FDA Access Data+1
Dalfampridine (fampridine, 4-AP). A potassium-channel blocker that can reduce downbeat nystagmus and improve gait in other neurologic diseases; approved to improve walking in MS; seizure risk rises with higher doses or renal impairment. FDA label/medication guide. FDA Access Data+1
Amifampridine (Firdapse®). Close relative of 4-AP; mainly approved for LEMS; discussed for cerebellar ocular motor symptoms on a case basis; seizure risk; specialist use only. FDA labeling/approval docs. FDA Access Data+1
Varenicline. Partial nicotinic agonist; small studies and case reports suggest benefit in downbeat nystagmus; monitor for neuropsychiatric effects per label. FDA Access Data+1
Riluzole. Glutamate-modulating agent with anti-excitotoxic rationale; mixed data in ataxias; approved for ALS; monitor liver enzymes. FDA labels. FDA Access Data+1
Dextromethorphan/quinidine (Nuedexta®). For pseudobulbar affect if present; monitor drug interactions and QT prolongation. FDA approval/label. FDA Access Data+1
Sertraline (or another SSRI). For anxiety/depression that worsen function; watch for GI upset, sleep change, and (rare) bleeding risk. FDA labels. FDA Access Data+1
Intrathecal baclofen (see surgery/procedures). For severe, generalized spasticity not controlled with tablets; requires pump implantation and close follow-up. FDA label (Lioresal® Intrathecal/Gablofen®). FDA Access Data+1
Important: Most medicines above are off-label for SCAR14. Use them only under a neurologist’s supervision, with clear target symptoms, start-low-go-slow titration, and regular safety monitoring. pn.bmj.com
Dietary molecular supplements
Coenzyme Q10 (CoQ10/ubiquinone or ubiquinol). Some hereditary ataxias due to primary CoQ10 deficiency improve with supplementation; benefit in non-deficiency ataxias is variable but plausible via mitochondrial support. Doses in reports range from ~15–30 mg/kg/day in children or up to 1200–2400 mg/day in adults; monitor for GI upset. PMC+2PMC+2
Vitamin E (alpha-tocopherol). Only disease-modifying when the ataxia is due to vitamin E deficiency (AVED); very high lifelong doses can stabilize or improve symptoms. In non-deficient SCAR14, routine high-dose vitamin E is not proven. Check a level first. NCBI+1
Omega-3 fatty acids. May support cardiovascular and general neural health; neurologic ataxia benefit is uncertain; consider for overall wellness if diet is low in fish. pn.bmj.com
Creatine monohydrate. Supports short-burst muscle energy; limited ataxia evidence; monitor for weight gain and cramps; ensure kidney health. pn.bmj.com
N-acetylcysteine (NAC). Antioxidant/glutathione precursor being explored for neuroprotection; evidence in ataxias is preliminary. Frontiers
Alpha-lipoic acid. Antioxidant with mixed neurologic data; may help neuropathic symptoms in diabetes; monitor for GI and hypoglycemia. pn.bmj.com
Vitamin D (optimize to normal). Supports bone health and fall-related fracture prevention; supplement only if low. pn.bmj.com
B-complex (B1, B6, B12) when deficient. Correcting documented deficiencies can improve neuropathy and fatigue. Avoid excess B6, which can itself cause neuropathy. pn.bmj.com
Magnesium (for cramps if low). Check levels first; GI side effects possible. pn.bmj.com
Zinc/selenium (only if deficient). Replace documented deficits to support immune and antioxidant enzymes; avoid high chronic doses. pn.bmj.com
Immunity-booster / regenerative / stem-cell” drugs
There are no approved immune-booster, regenerative, or stem-cell drugs for SCAR14. Below are areas sometimes discussed; all are investigational or supportive and should only be considered in trials or specialist care.
CoQ10 in proven primary CoQ10-deficiency ataxias (disease-specific, not SCAR14). Mechanism: mitochondrial electron transport support; dosing above. Evidence is mixed and genotype-dependent. PMC+1
Antioxidant strategies (e.g., NAC, alpha-lipoic acid). Mechanism: reduce oxidative stress; human ataxia data are limited. Frontiers
Neurotrophic modulation (riluzole). Mechanism: glutamate modulation; approved for ALS; mixed ataxia data; monitor liver tests. FDA Access Data
Cell-based therapies (experimental DBS-paired neurorehab concepts). Mechanism: neuromodulation rather than regeneration; early reports show tremor benefit in selected ataxias, not disease reversal. American Academy of Neurology
Gene-targeted approaches. Mechanism: correcting or bypassing SPTBN2 defects is a research goal; not clinically available yet. MDPI
Exercise-induced neuroplasticity (high-intensity, task-specific rehab). Mechanism: strengthens compensatory networks; current best “regenerative-like” option with real-world gains. PMC
Surgeries / procedures (when and why)
Intrathecal baclofen pump implantation for severe, generalized spasticity unresponsive to oral therapy (screening test dose first). Purpose: deliver baclofen directly into spinal fluid to reduce tone with fewer systemic side effects. Mechanism: GABA-B agonism at spinal interneurons. FDA Access Data+1
Percutaneous endoscopic gastrostomy (PEG) for prolonged unsafe swallowing/weight loss despite therapy. Purpose: secure nutrition and reduce aspiration risk. Mechanism: direct stomach access for feeding; done after careful multidisciplinary assessment. gutnliver.org+1
Deep brain stimulation (DBS) targeting thalamic VIM or cerebellar circuits for disabling tremor/dystonia in select cases. Purpose: symptom relief when medications fail. Evidence: case series and reviews show tremor improvement; ataxia itself generally does not improve. American Academy of Neurology+1
Orthopedic procedures (e.g., tendon releases, foot deformity correction) if contractures or deformities cause pain or prevent bracing. Purpose: improve comfort, fit of orthoses, and mobility. Mechanism: mechanical alignment. pn.bmj.com
Strabismus/oculomotor procedures in rare cases of fixed misalignment causing diplopia after failure of prism/therapy. Purpose: reduce double vision. pn.bmj.com
When to see a doctor (red flags)
See a neurologist urgently for new choking, repeated aspiration, rapid worsening, new seizures, severe depression or suicidal thoughts, sudden vision loss/double vision, or major falls with injury. Regular follow-up is needed to adjust therapy, review safety of medicines, and update genetic counseling as new data emerge. BioMed Central+1
What to eat & what to avoid
Eat: protein-adequate, calorie-sufficient meals; small frequent portions if fatigue. BioMed Central
Eat: soft, moist textures if swallowing is difficult (dietitian-guided). BioMed Central
Eat: fiber-rich foods and fluids to prevent constipation from low mobility. pn.bmj.com
Eat: sources of vitamin D and calcium if low (or supplement as advised). pn.bmj.com
Consider: CoQ10 only after discussing realistic goals; evidence is mixed outside deficiency states. PMC
Avoid: alcohol and sedative drugs that worsen balance. pn.bmj.com
Avoid: crash diets—weight loss can reduce strength and increase falls. BioMed Central
Avoid: very thin liquids if advised by a swallow therapist (use thickened fluids). BioMed Central
Avoid: high-dose supplements without a deficiency or plan—possible side effects and interactions. pn.bmj.com
Hydrate: dehydration increases dizziness and fall risk. pn.bmj.com
FAQs
1) Is SCAR14 the same as SCA14?
No. SCAR14 is recessive (usually SPTBN2); SCA14 is dominant (PRKCG). Different genetics and family risks. malacards.org+1
2) How is SCAR14 diagnosed?
By clinical exam, brain MRI, and genetic testing confirming two pathogenic SPTBN2 variants. SpringerLink
3) Can rehab really help a degenerative ataxia?
Yes. High-quality reviews show physiotherapy reduces ataxia severity and improves function. PMC
4) Are there disease-modifying drugs?
Not yet for SCAR14. Current treatments are symptom-targeted and preventative. pn.bmj.com
5) Are any ataxias treatable with vitamins?
Yes—vitamin E deficiency ataxia improves with high-dose vitamin E; that’s why we test levels. NCBI
6) What about CoQ10?
Effective in primary CoQ10 deficiency; outside that, benefit is uncertain; discuss goals and dosing with your clinician. PMC
7) Can eye symptoms improve?
Some patients get relief from memantine, dalfampridine, or varenicline for specific nystagmus types; this is off-label and monitored closely. FDA Access Data+1
8) When is a feeding tube considered?
If swallowing is unsafe for weeks and weight is falling, a PEG may prevent aspiration and malnutrition. gutnliver.org
9) Is DBS a cure?
No. It may reduce disabling tremor in select patients but does not reverse ataxia. American Academy of Neurology
10) How often should I follow up?
Typically every 6–12 months (or sooner if symptoms change) to adjust therapies and review safety. pn.bmj.com
11) Should family members be tested?
Carrier testing and genetic counseling are recommended for siblings and for family planning. NCBI
12) What makes falls more likely?
Poor lighting, sedative medications, alcohol, dehydration, and vision problems. Fixing these lowers risk. pn.bmj.com
13) Can school/work accommodations help?
Yes. Time-breaks, assistive tech, and mobility aids improve participation and safety. pn.bmj.com
14) Are clinical trials available?
Trials come and go; ask your neurologist or search reputable registries for hereditary ataxia studies. pn.bmj.com
15) What’s the outlook?
Course varies. Early rehab, nutrition, fall prevention, and addressing mood and vision issues can meaningfully improve daily life even without a cure. PMC,
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: October 14, 2025.
